Health Care • Biotechnology: Pharmaceutical Preparations
$186.65 ▲ +12.25
(+7.02%)
MKT CAP: $270.45B • VOL: 5.47M
52W L $153 52W H $213
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$157
MEDIAN
$209
MEAN
$213
HIGH
$254
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AZN TAPE
AZN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $225.85 | $214.65 | 2025-02-14 | $169.85 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $235.18 | $220.25 | 2025-02-06 | $175.45 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $212.78 | $205.32 | 2025-01-29 | $179.18 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $190.38 | — | 2025-01-17 | $182.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $164.25 | $177.32 | 2025-01-09 | $166.12 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $222.11 | $194.12 | 2024-12-18 | $162.39 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $181.05 | $188.52 | 2024-12-04 | $173.58 | -4.3% | 48% | C |